View in EDS

170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors.

Saved in:
Bibliographic Details
Title: 170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors.
Authors: Jeger, S.1 (AUTHOR), Schönborn-Kellenberger, O.2 (AUTHOR), De Winter, H.1 (AUTHOR), Steeghs, N.3 (AUTHOR), Gort, E.4 (AUTHOR), Gomez-Roca, C.5 (AUTHOR), Stavropoulou, V.1 (AUTHOR), Kenefeck, R.1 (AUTHOR), Fernandez, E.1 (AUTHOR), Ji, H.1 (AUTHOR), Marchand, C.1 (AUTHOR), Legenne, P.1 (AUTHOR), Cassier, P.6 (AUTHOR)
Source: Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1456-S1457. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2021.10.189